Yanina Balabanova

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 10

Top Topics

Atrial Fibrillation

Venous Thromboembolism

Direct Oral Anticoagulants

Clinical Practice

Top Venues

Expert opinion on drug safety

Drugs - real world outcomes

Clinical epidemiology

This page only lists publications with an associated author ORCID identifier.

Publications

Gunnar Brobert, Ana Ruigomez, Cristina Rebordosa, Annemarie Voss, Ron M C Herings, Elisabeth Smits, Karin M A Swart, Leif Friberg, Yanina Balabanova, Christine Tarenz, Kiliana Suzart-Woischnik, Montse Soriano Gabarró, Pareen Vora, Martin Homering, Tomasz Dyszynski, Gerd Nagel, Pablo Amaya, Luis Alberto García-Rodríguez
Challenges and lessons learned from a long-term postauthorisation safety study programme of rivaroxaban in Europe. BMJ open 14 (3) (2024)
Gunnar Brobert, Ana Ruigomez, Cristina Rebordosa, Annemarie Voss, Ron M C Herings, Elisabeth Smits, Karin M A Swart, Leif Friberg, Yanina Balabanova, Christine Tarenz, Kiliana Suzart-Woischnik, Montse Soriano Gabarró, Pareen Vora, Martin Homering, Tomasz Dyszynski, Gerd Nagel, Pablo Amaya, Luis Alberto García-Rodríguez
Challenges and lessons learned from a long-term postauthorisation safety study programme of rivaroxaban in Europe. BMJ open 14 (3) (2024)
Gunnar Brobert, Ana Ruigomez, Cristina Rebordosa, Annemarie Voss, Ron M C Herings, Elisabeth Smits, Karin M A Swart, Leif Friberg, Yanina Balabanova, Christine Tarenz, Kiliana Suzart-Woischnik, Montse Soriano Gabarró, Pareen Vora, Martin Homering, Tomasz Dyszynski, Gerd Nagel, Pablo Amaya, Luis Alberto García-Rodríguez
Challenges and lessons learned from a long-term postauthorisation safety study programme of rivaroxaban in Europe. BMJ open 14 (3) (2024)
Gunnar Brobert, Ana Ruigomez, Cristina Rebordosa, Annemarie Voss, Ron M C Herings, Elisabeth Smits, Karin M A Swart, Leif Friberg, Yanina Balabanova, Christine Tarenz, Kiliana Suzart-Woischnik, Montse Soriano Gabarró, Pareen Vora, Martin Homering, Tomasz Dyszynski, Gerd Nagel, Pablo Amaya, Luis Alberto García-Rodríguez
Challenges and lessons learned from a long-term postauthorisation safety study programme of rivaroxaban in Europe. BMJ open 14 (3) (2024)
Luis Alberto García-Rodríguez, Ana Ruigómez, Cristina Rebordosa, Annemarie Voss, Elisabeth Smits, Karin M A Swart, Yanina Balabanova, Kiliana Suzart-Woischnik, Gunnar Brobert, Ron M C Herings
Safety and effectiveness of rivaroxaban for prevention of stroke in patients with nonvalvular atrial fibrillation: analysis of routine clinical data from four countries. Expert opinion on drug safety (2023)
Annemarie Voss, Elisabeth Smits, Karin M A Swart, Yanina Balabanova, Gunnar Brobert, Kiliana Suzart-Woischnik, Ron M C Herings, Cristina Rebordosa, Ulrike Haug
Time Trends in Patient Characteristics of New Rivaroxaban Users with Atrial Fibrillation in Germany and the Netherlands. Drugs - real world outcomes (2023)
Antonio Gonzalez Perez, Yanina Balabanova, María Eugenia Sáez, Gunnar Brobert, Luis Alberto García-Rodríguez
Acute Kidney Injury in Patients with Non-Valvular Atrial Fibrillation Treated with Rivaroxaban or Warfarin: A Population-Based Study from the United Kingdom. Clinical epidemiology 14 (2022)
Yanina Balabanova, Bahman Farahmand, Hans Garmo, Pär Stattin, Gunnar Brobert
Risk of venous thromboembolism in men with prostate cancer compared with men in the general population: a nationwide population-based cohort study in Sweden. BMJ open 12 (5) (2022)
Laurie Zografos, Dan Wolin, Elizabeth Andrews, Brian Calingaert, Yanina Balabanova, Andrea Horvat-Bröcker, Christine Tarenz, Kiliana Suzart-Woischnik
Evaluating patient and physician knowledge of risks and safe use of rivaroxaban: a survey across four countries. Expert opinion on drug safety (2021)
Luis Alberto García-Rodríguez, Mari-Ann Wallander, Leif Friberg, Ana Ruigómez, Cristina Rebordosa, Irene D Bezemer, Ron M C Herings, Saad Shakir, Alison Evans, Miranda Davies, Kiliana Suzart-Woischnik, Pareen Vora, Yanina Balabanova, Montse Soriano Gabarró, Gunnar Brobert
Rationale and design of a European epidemiological post-authorization safety study (PASS) program: rivaroxaban use in routine clinical practice. Expert opinion on drug safety 19 (11) (2020)